These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 26657335)

  • 1. Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target.
    Asim M; Massie CE; Orafidiya F; Pértega-Gomes N; Warren AY; Esmaeili M; Selth LA; Zecchini HI; Luko K; Qureshi A; Baridi A; Menon S; Madhu B; Escriu C; Lyons S; Vowler SL; Zecchini VR; Shaw G; Hessenkemper W; Russell R; Mohammed H; Stefanos N; Lynch AG; Grigorenko E; D'Santos C; Taylor C; Lamb A; Sriranjan R; Yang J; Stark R; Dehm SM; Rennie PS; Carroll JS; Griffiths JR; Tavaré S; Mills IG; McEwan IJ; Baniahmad A; Tilley WD; Neal DE
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26657335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression.
    Lin XM; Hu L; Gu J; Wang RY; Li L; Tang J; Zhang BH; Yan XZ; Zhu YJ; Hu CL; Zhou WP; Li S; Liu JF; Gonzalez FJ; Wu MC; Wang HY; Chen L
    Gastroenterology; 2017 Apr; 152(5):1187-1202. PubMed ID: 28065789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
    Zhang X; Wang Y; Ning Y
    Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoisoliquiritin exerts tumor suppressive effects on prostate cancer by repressing androgen receptor activity.
    Chen C; Shao R; Li B; Zhai Y; Wang T; Li X; Miao L; Huang J; Liu R; Liu E; Zhu Y; Gao X; Zhang H; Wang Y
    Phytomedicine; 2021 May; 85():153514. PubMed ID: 33676083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
    Mostaghel EA; Nelson PS; Lange P; Lin DW; Taplin ME; Balk S; Ellis W; Kantoff P; Marck B; Tamae D; Matsumoto AM; True LD; Vessella R; Penning T; Hunter Merrill R; Gulati R; Montgomery B
    J Clin Oncol; 2014 Jan; 32(3):229-37. PubMed ID: 24323034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variants.
    Sun F; Indran IR; Zhang ZW; Tan MH; Li Y; Lim ZL; Hua R; Yang C; Soon FF; Li J; Xu HE; Cheung E; Yong EL
    Carcinogenesis; 2015 Jul; 36(7):757-68. PubMed ID: 25908644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
    Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
    Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.
    Schmidt LJ; Duncan K; Yadav N; Regan KM; Verone AR; Lohse CM; Pop EA; Attwood K; Wilding G; Mohler JL; Sebo TJ; Tindall DJ; Heemers HV
    Mol Endocrinol; 2012 May; 26(5):716-35. PubMed ID: 22456196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
    Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
    Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. White button mushroom (Agaricus bisporus) disrupts androgen receptor signaling in human prostate cancer cells and patient-derived xenograft.
    Wang X; Ha D; Mori H; Chen S
    J Nutr Biochem; 2021 Mar; 89():108580. PubMed ID: 33388344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
    Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of androgen receptor expression by Z-isochaihulactone mediated by the JNK signaling pathway and might be related to cytotoxicity in prostate cancer.
    Liu PY; Lin SZ; Sheu JJ; Lin CT; Lin PC; Chou YW; Huang MH; Chiou TW; Harn HJ
    Prostate; 2013 Apr; 73(5):531-41. PubMed ID: 23038474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SIRT7 depletion inhibits cell proliferation and androgen-induced autophagy by suppressing the AR signaling in prostate cancer.
    Ding M; Jiang CY; Zhang Y; Zhao J; Han BM; Xia SJ
    J Exp Clin Cancer Res; 2020 Feb; 39(1):28. PubMed ID: 32019578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
    Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
    Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines.
    Ramamurthy VP; Ramalingam S; Gediya L; Kwegyir-Afful AK; Njar VC
    Oncotarget; 2015 Feb; 6(5):3195-210. PubMed ID: 25605250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis.
    Mostaghel EA; Morgan A; Zhang X; Marck BT; Xia J; Hunter-Merrill R; Gulati R; Plymate S; Vessella RL; Corey E; Higano CS; Matsumoto AM; Montgomery RB; Nelson PS
    PLoS One; 2014; 9(10):e111545. PubMed ID: 25356728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of androgen-induced regulator ARD1 inhibits androgen receptor acetylation and prostate tumorigenesis.
    Wang Z; Wang Z; Guo J; Li Y; Bavarva JH; Qian C; Brahimi-Horn MC; Tan D; Liu W
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3053-8. PubMed ID: 22315407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.
    Xie N; Cheng H; Lin D; Liu L; Yang O; Jia L; Fazli L; Gleave ME; Wang Y; Rennie P; Dong X
    Int J Cancer; 2015 Feb; 136(4):E27-38. PubMed ID: 25138562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Independence of HIF1a and androgen signaling pathways in prostate cancer.
    Tran MGB; Bibby BAS; Yang L; Lo F; Warren AY; Shukla D; Osborne M; Hadfield J; Carroll T; Stark R; Scott H; Ramos-Montoya A; Massie C; Maxwell P; West CML; Mills IG; Neal DE
    BMC Cancer; 2020 May; 20(1):469. PubMed ID: 32450824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.
    Centenera MM; Scott JS; Machiels J; Nassar ZD; Miller DC; Zinonos I; Dehairs J; Burvenich IJG; Zadra G; Chetta PM; Bango C; Evergren E; Ryan NK; Gillis JL; Mah CY; Tieu T; Hanson AR; Carelli R; Bloch K; Panagopoulos V; Waelkens E; Derua R; Williams ED; Evdokiou A; Cifuentes-Rius A; Voelcker NH; Mills IG; Tilley WD; Scott AM; Loda M; Selth LA; Swinnen JV; Butler LM
    Cancer Res; 2021 Apr; 81(7):1704-1718. PubMed ID: 33547161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.